Efficacy and safety of infliximab vs. Methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)

British Journal of Dermatology

Volumn 165, Issue 5, 2011, Pages 1109-1117

  Barker, J ^a   Hoffmann, M ^b   Wozel, G ^c   Ortonne, J P ^d   Zheng, H ^e   Van Hoogstraten, H ^e   Reich, K ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Practice of Dermatology and Allergology   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e MERCK RESEARCH LABORATORIES   (United States)

^f DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; LIVER FUNCTION TEST; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PHASE 3 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX; RHINOPHARYNGITIS; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; PSORIASIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856302095     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10615.x     Document Type: Article

References (16)

1. National Psoriasis Foundation. About Psoriasis: Statistics. Available at: http://www.psoriasis.org/netcommunity/learn-statistics (last accessed 5 September 2011).
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Questions and Answers about Psoriasis. NIH Publication No. 09-5040, 2009. Available at http://www.niams.nih.gov/Health-Info/Psoriasis/default.asp (last accessed 5 September 2011).
3. Lecluse LLA, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European 'Psonet' Initiative. Dermatology 2009; 218:347-56.
4. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204. (Pubitemid 36398393)
5. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-912. (Pubitemid 40627816)
6. Pathirana D, Ormerod AD, Saiag P et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2):5-70.
7. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534-42. (Pubitemid 39278071)
8. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multi-centre, double-blind trial. Lancet 2005; 366:1367-74. (Pubitemid 41443403)
9. Menter A, Feldman S, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe psoriasis. J Am Acad Dermatol 2007; 56:31.e1-15.
10. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153:486-97. (Pubitemid 41248202)
11. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology 2000; 39:321-7. (Pubitemid 30204219)
12. The EuroQoL Group. EuroQoL - a new facility for the measurement of health-related quality of life. The EuroQoL Group. Health Policy 1990; 16:199-208.
13. Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154:1161-8. (Pubitemid 43727400)
14. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4:35.
15. Heydendael VMR, Spuls PL, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658-65. (Pubitemid 36975998)
16. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558-66. (Pubitemid 351239154)